Drug Profile
Research programme: anticancer therapeutics - Molecular Templates/Takeda Oncology
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Molecular Templates; Takeda Oncology
- Class Antineoplastics; Peptides
- Mechanism of Action CD38 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from in-vitro and preclinical studies presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 28 Mar 2019 Molecular Templates and Takeda plan a phase I trial of TAK 169 for Multiple myeloma (Second-line therapy or greater) in USA in September 2019 (IV) (NCT04017130)